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Abstract
Background: The major obstacle to cure of HIV type-1 infection is the presence of the HIV reservoir, hidden from
the immune system and insensitive to combined antiretroviral therapy (cART). Eradication approaches have been
hindered by the difficulty for accurately monitoring its size in vivo, especially in the lymphoid organs. Humanized
mouse models are a valuable tool for systematically assess the efficacy of therapeutic interventions in reducing the
HIV reservoir. Nonetheless, persistence of the HIV reservoir over time, in the presence of cART, has yet to be
analyzed in this in vivo model.
Findings: We found that the proviral DNA as well as the total DNA were very stable in the spleen and mesenteric
lymph node irrespective of the length of cART. Notably, the amount of proviral DNA was very similar in the spleen
and lymph node. Furthermore, we observed a correlation between the percentage of splenic human CD4+ T-cells
with total HIV DNA, between the number of human CD38 + CD8+ T-cells in the spleen with the amount of
integrated HIV DNA, and eventually between the hCD4/hCD8 ratio in the spleen with integrated as well as total HIV
DNA implying that the CD8+ T cells influence the size of the HIV reservoir.
Conclusions: Here, we demonstrated the stability of this reservoir in humanized mice irrespective of the length of
cART, confirming the relevancy of this model for HIV latency eradication investigations. Notably, we also found
correlates between the frequency of CD4+ T-cells, their activation status and viral parameters, which were
analogous to the ones in HIV-infected patients. Thus, hu-mice represent a very valuable HIV latency model.
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Introduction
The cure for HIV is impeded by the latent reservoir of
HIV, which is established during acute HIV infection, is
non-responsive to cART [1, 2] and has a very slow decay
rate with a ̴ t½ of 44 months [3, 4]. Memory CD4+
T-cells with ̴ 1/10e5 latently infected [5] are the major
cell subset making up this latent reservoir [6]. The per-
sistence of this reservoir might be mediated by either
cellular intrinsic longevity [7] and self-renewal capacity
[8] or homeostatic proliferation through cytokines and
cell-cell interactions [6, 9].
Several humanized mouse (hu-mice) models recapitulate
key features of HIV infection [10–13] and have been suc-
cessfully used for studying various eradication approaches
[14–17]. However, this model has yet to be validated for
some key aspects of HIV latency such as for its stability
over time. Furthermore, hu-mice are chimeric animals,
where the human hematopoietic turnover might be altered
[18]. Partial interspecies cross-reactivity between murine
cytokines/chemokines or MHC and co-stimulatory mole-
cules with their human cognate receptors, might reduce
the survival capacity of engrafted human cells, possibly
affecting the decay of the latent reservoir.
Here we explored the intricate network between the
HIV reservoir and its potential impact on HIV pathogen-
esis in HIV-infected hu-mice. In particular, we quantified
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the HIV DNA in hu-mice treated for different length with
cART and explored whether it correlated with the viral
load before cART, the number of target cells and immune
activation markers. We will explicitly use the term HIV
reservoir as measuring HIV DNA will capture defective as
well as infectious HIV particles [19]. The term latent
reservoir is primarily reserved for latently infected cells
which retain the capacity to produce infectious virus parti-
cles [20] and requires assays measuring virus particle pro-
duction or transcribed HIV mRNA following activation of
latently HIV-infected cells [19].
Materials and methods
Generation of humanized mice
Immunodeficient NOD-scid IL2Rgammanull (NSG) mice
were obtained from the Jackson laboratory (#005557) and
bred in a specific pathogen free (SPF) animal facility (Ito
et al. 2002). Newborn mice were sublethally irradiated
(1Gy) within 5 days of birth and 2e105human cord
blood-derived CD34+ cells were injected intra-hepatically.
These CD34+ cells were isolated using immunomagnetic
beads (Miltenyi, #130–046-702) after gradient centrifuga-
tion (Axis-Shield PoC AS, Norway). The purity (> 90%) of
the CD34+ was determined by flow-cytometry. 12 weeks
after human HSPCs’ transplantation, human reconstitu-
tion in the blood was analyzed by flow-cytometry with the
following markers; hCD45, hCD19, hCD3, hCD4, hCD8.
Animals with more than 10% of human reconstitution
were selected for HIV infection.
HIV infection
293 T cells, obtained from ATCC® CRL-3216™, were cul-
tured in DMEM medium (Sigma, D6429), supplemented
with 10% of FBS (Millipore, S0615) and 1% penicillin/
streptomycin (Gibco, #15140–122) and transfected with
20 μg of lab-strain Yu2 plasmid DNA, using Polyethyle-
nimine (PEI, 2 μg/μg of plasmid, Polyscience #23966).
After 48 h, the medium was collected, 0.22 μm-filtered
(Steriflip, Millipore, SCGP00525) and stored at − 80 °C
until use. The 50% of tissue culture infectious dose
(TCID50) was determined by incubating 1:5 serial dilu-
tion of the HIV virus stock, in quadruplicate, with 2*105
activated PBMCs for 7 days. TCID50 was estimated
based on the number of p24-positive wells and the Reed
and Muench calculation. Isoflurane-anesthetized animals
were intra-peritoneally injected with HIV Yu2 (2*105
TCID50). Four weeks later, viral dissemination was
determined using the Cobas® Amplicor technology
(Roche). Upon viral replication, animals were fed with
cART-supplemented food pellet until euthanasia. Con-
firmation of undetectable HIV RNA copies/ml (limit
of detection of 440 copies/ml) was determined after 5
weeks post cART initiation. Animals were euthanized
at viral dissemination (week − 1), at viral suppression
(week 5) and after 6, 9, 13 and 17 weeks of cART.
cART-supplemented food pellet
Production of cART-supplemented food pellet was adapted
[10]. Briefly, 4700mg/kg of Raltegravir (Isentress, MSD
Merck Sharp & Dohme, AG), 540mg/kg of Tenofovir dis-
oprexil (TDF, Viread, Gilead Science Switzerland Sàrl) and
540mg/kg of 3TC (Lamivudin, ViiV, Healthcare GmbH)
were mixed with ground protein-rich, vitamin-fortified
food (Nafag 3432, Provimi Kliba AG, Switzerland), subse-
quently gamma-irradiated with 25 kGy.
Peripheral blood and tissues collection
Blood was collected retro-orbitally in an EDTA-coated
tube (BD microtainer K2E, #365975), after 4 weeks of
HIV infection, 5 weeks of cART-supplemented food
initiation and at the euthanasia. Separation of the plasma
and the cell pellet was obtained by low speed centrifuga-
tion (3′000 rpm for 10min). Organs were meshed in
MACS buffer (PBS supplemented with 2% FBS and 2
mM of EDTA (Invitrogen, #15575–038) using a 70 μm
strainer (Falcon 352,350) and the syringe plug (B/braun
Injekt, 10 ml, #4606108). Splenocytes were separated
from the erythrocytes by gradient centrifugation, and the
lymph nodes were lysed with 1 ml of ACK buffer (Gibco,
A1049201). PBS was used for the washing steps. Cell
suspensions from organs were counted, stained for
flow-cytometry analysis and frozen as dry pellet for the
PCR analysis. The pool of some specimens with low cell
numbers was performed according to the time of sup-
pression and the baseline viral load. We euthanized mice
prior and 5, 6, 9, 13 and 17 weeks post-cART (see legend
to Fig. 1 for the number of mice euthanized).
Antibodies and reagents
Humanized mice-derived samples were analyzed for
their human cell distribution by flow-cytometry using
the following antibodies from Biolegend: CD19-APC
(#302212), CD3-PE (#300308), CD4-PECy7 (#300512),
CD8-Brilliant Violet 421 (#301036). CD38-PerCPCy5.5
(#303521) and HLA-DR-FITC (#307604). The pan-human
marker CD45-Krome Orange, was obtained from Beckman
Coulter (PN96416).
Flow cytometry
Blood and organs collected from animals were incubated
with the cell-surface marker antibody at an optimized di-
lution in FACS buffer (PBS containing 2mM EDTA, 0.1%
sodium azide and 10% FCS) for 20min at 4 °C. After stain-
ing, blood samples were lysed with 1x BD FACS™ Lysing
solution (BD, #349202) for 10min at room temperature,
subsequently washed with PBS, whereas cell suspension of
organs were washed with FACS buffer. Stained cells were
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fixed with 1% paraformaldehyde (PFA) in PBS, acquired
on a CyAn TM ADP Analyzer (Beckman Coulter) and
data were analyzed using FlowJo (version V.10.0.8). We
defined the live cells by the side scatter/forward scatter
gate and then quantified the number of cells by the spe-
cific marker of interest.
DNA extraction and quantitative real-time PCR for total
HIV gag
DNA was extracted from organs using the QIAmp
DNA blood minikit (Qiagen, #51106), following manu-
facturer’s instructions. DNA elution was performed
using 100 μl of 10 mM Tris-HCl at pH 8 (Affymetrix,
#1185-53-1). The eluate was used for a second round
of elution to maximize the DNA recovery. DNA
concentration was quantified using the Quant-iTTM
PicoGreen® dsDNA Assay (Thermofisher Scientific,
P11496). Subsequently, total HIV DNA copies and hu-
man cell quantification was performed using 100 ng of
DNA per replicate. Amplification of gag sequence was
performed using the following primers-probe; 1 μM of
Forward: 5-CAAGCAGCCATGCAAATGTTAAAAGA-3;
1 μM of Reverse: 5-TACTAGTAGTTCCTGCTATGTCA
CTTCC-3 and 350 nM of the probe: 5-FAM-TGCA
GCTTCCTCATTGATGGT-BHQ1–3. Human cell quan-
tification, within a mouse background, relayed on diver-
gence in the RPP38 gene sequence [21], which is detected
using 400 nM of primers (Forward: 5-TCACGACAC
CTCTGCTTTA-3 and Reverse: 5-AGCGGTGAGAAAC
TAGGAA-3) with 100 nM of probe (5-FAM-AAGT
TGCTTCACACTGGAACGCTTGC-BHQ1–3). The PCR
mix contained 2x Maxima Hot Start (ThermoFischer
Scientific, K1052), Molecular grade water (Applichem,
A7398–0500) and Rox (dilution 1/100, ThermoFischer
Scientific, #12223012), as a reference dye. PCRs were run
on an ABI Prism 7500 cycler with these cycling condi-
tions: 5 min at 95 °C followed by 50 cycles of 5 s at 95 °C
and 30 s at 60 °C, where the annealing, elongation and sig-
nal detection occur. Standard curves for the copy number
determination were prepared using different ratios of cell
lines, which DNA was independently extracted. In brief,
increasing concentration of either 8E5 (NIH, cat. 95, 2
copies/genomes) into Jurkat T cells (ATCC® TIB152TM),
for the gag standard curve or Jurkat T cells into EL4
(mouse leukemic cell line ATCC® TIB39TM), for the
human standard curve, were used at 100 ng per replicate,
which approximate 15′000 human cells or 30′000 gag
copy number.
Alu-PCR
Determination of integrated provirus DNA was adapted
from previously described methods by Spiegelaere et al.
2014. In brief, 50 ng of DNA per replicate (96 wells plate,
Starlab, I1402–9700) was amplified with either alu (100 nM,
5-GCGCGGTGGCTCACGCCTGTAAT-3) and gag (600
nM, 5-CTTAATACTGACGCTCTCGCACC-3) or gag only
A B C
D E F G
Fig. 1 Stability of the HIV reservoir in humanized mice in the spleen and lymph node. Infected NSG mice (n = 36) were euthanized prior to cART
(n = 3) and after documented viral suppression at 5 (n = 2), 6 (n = 10), 9 (n = 9), 13 (n = 7) and 17 (n = 5) weeks of treatment. a Viral load in hu-
mice over time before and after treatment with cART. Spleen and lymph nodes were removed at euthanasia and HIV provirus (b) and total HIV
DNA/millions of hCD45+ cells (c) quantified over time shown in blue for the lymph node and in red for the spleen (mean ± SEM). d Correlation
between proviruses/millions of hCD45+ cells between the spleen and the lymph node from the same animal or pool of animals. e Correlation
between total HIV DNA between the lymph node and the spleen from the same animal or pool of animals, (P = 0.2089, r = 0.311). f and g
Correlation between proviruses and total HIV DNA in the spleen or the lymph node, respectively. Because of the low yield of lymphatic tissues in
some mice, we were forced to pool the lymphatic tissues of some mice, which had a similar peak viral load. In fact in some mice we were not
able to retrieve lymph node tissue. Thus, the data presented for the lymph nodes are based on 26 mice euthanized and eventually 14 (b) and 16
(c) data points, and for the spleen on 36 mice with 24 data points
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primers in a final volume of 50 μl. The cycling conditions
are the following: 5 s at 95 °C, 40 cycles of 45 s at 95 °C, 60 s
at 58 °C and 210 s at 72 °C with a final elongation of 10min
at 72 °C. The repetitive sampling was performed with 42
replicates and the amount of DNA depended on the
total HIV copy number determined previously. Then,
10 μl per well is transferred into 10 μl of the nested
PCR mix, without water, for the amplification of LTR
sequence. The Forward (5-ATAAAGCTTGCCTTGAGT
G-3) and the reverse (5-TGACTAAAAGGGTCTGAGG
GATCTCTA GTTACCAG-3) primers were used at 1 μM
and the LNA probe (Eurogentec, 5-FAM-TG-lnT-G-lnT-
GC-lnC-C-lnG-T-BHQ1–3) at 300 nM. The PCR conditions
were as followed: 95 °C for 5min; 50 cycles at 95 °C for 10 s,
55 °C for 5 s and 60 °C for 40 s with a final elongation of 10
min at 72 °C. Alu-gag and gag only CT values were trans-
ferred into the excel sheet from Spiegelaere with the amount
of human cells per well, determined using the human quan-
tification PCR described above. In addition, the estimation
of integrated proviruses required the assessment of a
PCR-intrinsic error, which has been calculated using a
standard curve of J-lat clone 9.2 (NIH, #9848) and 15.4
(NIH, #9850), 8E5 as well as ACH2 cells (NIH, #349) cul-
tured with Efavirenz (1 μM, Sigma, SML0536) and AZT
(5 μM, Sigma, A2169) with a Jurkat T cell background. The
error obtained from the standard 10/106, 100/106 and
103/106 (standard deviation of 0.028) was 0.4516.
Statistics
The software GraphPad Prism Version 5.04 was used for
doing statistics. For comparing total HIV DNA or proviral
DNA prior vs after cART, we used the Mann-Whitney
test. Stability of integrated proviruses or total HIV DNA
over time was determined by ANOVA and linear regres-
sion between all the data sets. For investigating correla-
tions between the various parameters, we used the
Spearman’s rank-order correlation test.
Results and discussion
In humans, many factors are implicated in the size of the
HIV DNA reservoir [22]. Among others, it has been
shown that the pool of latently infected cells continuously
expands at variable rates in cART naïve HIV-infected pa-
tients, depending on the patient’s cytotoxic T lymphocytes
(CTL) response [23, 24] and the immune activation [25].
Furthermore, the CD4+ T-cell count at the time of cART
initiation correlated negatively with the total HIV DNA in
the blood and in the gut [26]. Markers of immune activa-
tion were predictors of proviral DNA [27]. In cART
treated patients, it was shown that HIV integrates prefer-
entially at specific sites, favoring their proliferation [28,
29]. Thus, HIV DNA is not a stochastic process.
The generation of hu-mice has allowed effective HIV
knowledge expansion and straightforward therapeutic
approach evaluations [30]. However, comprehensive
characterization of HIV latency is lacking. Indeed, pa-
rameters influencing the size of the HIV reservoir are
unknown and likely numerous, i.e., chimerism level,
immune activation and cellular proliferation, sensitivity
of the graft to HIV, infection dose, initial viral load and
duration of HIV disease before cART initiation [31].
Exact quantification of the HIV reservoir is crucial for
judging any intervention targeting the latent reservoir.
Here we explored the persistence of the HIV reservoir
depending upon the length of cART and in the intricate
context of HIV pathogenesis. Notably, latency is interro-
gated either by viral outgrowth assays (VOA) or by
PCR-based methods [32, 33]. VOA detect solely the
number of cells productively infected. In contrast, DNA
PCR-based methods detect all HIV genomes irrespective
whether they are fully infectious or defect. Defect proviruses
may still produce viral antigens or replication-incompetent
HIV that activates the immune system and thereby contrib-
utes to HIV pathogenesis. Thus, we interrogated here the
dynamic of the HIV reservoir by quantifying total and
proviral HIV DNA and by measuring a number of cellular
markers.
Briefly, we infected hu-mice i.p. with the CCR5-tropic
strain, YU-2 and started cART consistently 4 weeks later,
since length of natural HIV infection is a factor influen-
cing the size of the HIV reservoir. Notably, HIV dissem-
ination occurred within 4 weeks following HIV infection,
defined as baseline viral load, and HIV replication was
suppressed within 5 weeks of cART (Fig. 1a).
We treated the mice up to 17 weeks (Fig. 1a). Notably,
we noticed that total HIV DNA in the spleen prior to
cART differed significantly from the ones under cART
(avg ± sem of total HIV DNA/mio CD45+ cells prior
(n = 3) vs after start of cART (n = 21): 17605 ± 15,042 vs
1639 ± 712, p = 0.036 (Mann Whitney test)) whereas this
was not the case for integrated DNA (avg ± sem of proviral
copies/mio CD45+ cells prior vs after: 29032 ± 16,762 vs
45,505 ± 3383; p = 0.0809). The rapid decay observed for
total HIV DNA is most likely due to the decay of linear
unintegrated HIV DNA [34] – integrated forms decay
more slowly [35]. These data are consistent with observa-
tions obtained in HIV-infected humans [34, 35].
We then wondered whether the length of cART has
any impact on the size of the HIV reservoir in the
HIV-infected hu-mice. Once the viral load was sup-
pressed, the proviral DNA as well as the total HIV DNA
were very stable in the spleen and the mesenteric lymph
node (mLN) and comparable over the entire 12 weeks
observation period independent of the length hu-mice
received cART (Fig. 1b and c). Notably, the value of total
HIV DNA at week 13 in the mLN was unusual and we
considered it as an outlier since the value at week 16
was superimposed again. In human, HIV DNA shows a
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bi-exponential decay phase [36] with a first half-life
based on mathematical modelling of 113 days and a
second half-life of years [37]. At least for the 12 weeks
once HIV RNA was suppressed, (i.e., first documented
suppression of viral load at week 5, total duration of
cART 17 weeks), we did not see a decay of the HIV
DNA. The discrepancy between decay rates in this HIV
mouse latency model and humans may be inherent to
the mouse model, the distinct lymphoid tissues exam-
ined (i.e., spleen and lymph nodes in mice vs PBMCs in
human) or explained by the large inter-individual het-
erogeneity of HIV DNA seen in mice and patients [35],
and the rather limited number of n = 33 mice used to
look into this issue. Notably, the tiny amount of PBMCs
in blood from humanized mice preclude this kind of
analysis, and correspondingly we were not able to per-
form a direct comparison of identical lymphoid tissue
specimens.
Importantly, the amount of proviruses in the spleen
and the mLN from the same animal or pool of animals
correlated significantly (Fig. 1d), indicating that identical
pathogenic processes underlie the establishment of the
HIV reservoir in the two lymphoid compartments. This
correlation, between spleen and mLN, was not observed
for total HIV DNA (Fig. 1e), pointing to distinct proper-
ties in these two lymphoid compartments as related to
HIV DNA stability or/and cellular proliferation rate. As
previously shown [6, 27, 38], we found a strong correl-
ation between the integrated and the total HIV DNA per
million of hCD45+ in the spleen as well as in the mLN
(Fig. 1f and g). The similar amount of integrated (Fig. 1b)
and total HIV DNA (Fig. 1c) during productive infection
(at − 1 week of cART) could be due to different sensitiv-
ities of the PCR methods used. Therefore, the values ob-
tained for both parameters cannot be directly compared;
their relationship, however, remains valid for understand-
ing the dynamics of both compartments. Similar to hu-
man [23], the size of the HIV reservoir was highly variable
between the individual animals. Notably, the gut associ-
ated lymphoid tissues (GALT) is a major site of HIV repli-
cation early in HIV infection [39] and the mLN is crucial
for the induction and the regulation of specific immune
responses initiated in the gut [40]. The ability to study
HIV latency in the mLN is a clear additional benefit of
HIV-infected humanized mice. In particular, it enables
to explore the penetrance and efficacy of latency revers-
ing agents in lymphoid tissues, as the penetrance of
ART has been shown to vary depending the lymphoid
organ analyzed [41].
Association between immune activation, especially ac-
tivated hCD4+ and hCD8+ cells, and viral replication, in
the absence of cART, has been widely reported in pa-
tients [25, 42]. Here, we found a tendency of correlation
between the baseline viral load and the frequency of
HLA-DR + CD38+ hCD4+ (Fig. 2a) and hCD8+ T cells
(Fig. 2b) in hu-mice, recapitulating HIV features in
HIV-infected individuals [42–44]. As reported [25], we
could not find any correlation between the amount of
proviruses under cART and baseline viral load (Fig. 2c)
[45, 46]. Of note, the frequency of hCD45+ or hCD4+
T-cells at the time of HIV infection or after 4 weeks was
neither associated with the baseline viral load nor with
the amount of integrated HIV DNA (data not shown).
These data refuted the chimerism level or the frequency
of target cells, respectively, as relevant indicators of HIV
viral load and size of the HIV reservoir in hu-mice.
We wondered whether the size of the HIV reservoir
was dependent on the hCD4+ T-cells. Indeed, the per-
centage of splenic hCD4+ T cells correlated with total
HIV DNA (Fig. 2d). There was a trend between the per-
centage of splenic hCD4 cells and the proviral DNA
(P = 0.1318, r = 0.3165). Strikingly, we also observed a
correlation between the hCD4/hCD8 ratio in the spleen
with integrated as well as total HIV DNA (Fig. 2e and f)
implying that the CD8+ T cells influence the size of the
HIV reservoir.
The ratio of integrated/total HIV DNA correlated
negatively with the frequency of hCD4+ T-cells in the
spleen (Fig. 2g). These findings could be explained by high
hCD4+ T-cell proliferation in response to low hCD4 prior
to cART [6], thereby increasing the integrated/total HIV
DNA ratio by diluting the total HIV DNA. Alternatively,
mice with a higher percentage of CD4+ T-cells could have
more cells prone to pre-integration latency, and that the
number of cells resulting eventually in post-integration
latency (proviral DNA) is not affected by the height of
CD4+ T-cells. We did not observe such a correlation
when looking at the total DNA in the mLN. Irrespect-
ive of differences in the lymphoid compartment stud-
ied, these data confirm CD4+ T-cells as prominent HIV
reservoir in hu-mice. The persistence of HIV-infected
CD4+ T-cells in hu-mice under cART is most likely
maintained through endogenous murine IL-7 driven
homeostatic proliferation [47].
We also found that the amount of integrated HIV DNA
correlated with the number of CD38 + hCD8+ T-cells in
the spleen (Fig. 2h). These data are reminiscent of recent
findings obtained in humans, i.e., in the blood proviral
DNA correlated with the frequency of HLA-DR+ CD8+
T-cells [27] and in the gut total HIV DNA with singly acti-
vated CD8+ T-cells (CD38+ or CD69+) [48, 49]. We did
not observe any correlation between total HIV DNA and
activated cells, including HLA-DR+ CD38+ CD8+ T-cells,
implying that amount of total HIV DNA and cellular
activation are subjected to distinct mechanism(s).
The data we present complement very nicely the data
reported by Arainga et al. [50]. They identified the central
memory T-cells as the dominant latently HIV infected
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T-cell in HIV-infected hu mice treated for 4 weeks with
cART. Besides and very importantly, they found that ma-
ture macrophages harbored also proviral DNA.
In summary, we demonstrate that the HIV reservoir as
quantified by HIV DNA in the spleen and lymph nodes is
stable over a cART treatment period of 17 weeks. Rather
all previous reports studied the effects of cART in
HIV-infected hu mice for at most ≈6–8 weeks. In those
previous studies, we and others showed the successful re-
versal of latency by either conventional or modified viral
outgrowth assays or viral rebound after interruption of
cART [10, 11, 51, 52]. Notably, and consistent with our
data, Lavender et al. showed viral rebound after 18 weeks
of cART mediated viral suppression [53]. We also report
here that the HIV DNA correlates with immune activa-
tion, the number of HIV target cells present and that it is
apparently affected by the CD8+ T-cell population. Not-
ably, first studies were recently published examining “kick”
and “kill” strategies in HIV-infected hu-mice [14, 54].
A large number of different background mouse strains
are today available which upon transplantation of human
CD34+ cells, present different functional immune cell ac-
tivities, among others functional CD8+ and NK cells [55].
Thus, compounds which act indirectly on HIV-infected
cells can also be explored for their effects on the HIV
reservoir. Thus, humanized mice represent a very attract-
ive in vivo HIV latency model [56].
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Fig. 2 Association between the reservoir size, viral load, hCD4+ T cells and immune activation. a, b Correlation between the viral load and the
percentage of HLADR+CD38 + hCD4+ (a) and hCD8+ T-cells (b) in the blood at 4 weeks p.i.. c Correlation between number of proviruses/millions of
hCD45+ cells in the spleen with the baseline viral load (P = 0.4626, r = 0.157). d Correlation between total HIV DNA/millions of hCD45+ cells in the
spleen with the blood frequency of CD4+ T cells at 4 weeks p.i.. e and f Correlation between proviruses and total HIV DNA with the CD4+/CD8+ T-cell
ratio in the spleen. g Correlation between the ratio proviruses/total HIV DNA with the frequency of CD4+ T cells in the spleen. h Correlation between
the number of proviruses/millions of hCD45+ cells with the percentage of CD38+ hCD8+ T cells in the spleen. i Correlation between the total HIV
DNA/millions of hCD45+ cells with the frequency of HLADR+CD38+ hCD8+
Rochat et al. Virology Journal          (2018) 15:191 Page 6 of 8
focus program Human Hemato-Lymphatic Diseases of the University of
Zurich, .
Authors’ contributions
MAR and RFS elaborated the concept of this study, MAR and ES did all the
experimental work; MAR, DL, AA, SI, AF took care of the breeding and
generation of humanized mice. MAR and SPK performed the statistical
analysis. MAR and RFS wrote the manuscript. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
All humanized mouse experiments as well as the procurement of human
cord blood were approved by ethical committees of the University of Zurich
and the Federal Veterinary Departments. The experiments were following
the local guidelines (TschV, Zurich) and the Swiss animal protection law
(TschG). Human cord blood was obtained with informed written consent of
the parents and processed anonymously.
Consent for publication
All authors consent for publication.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Received: 12 July 2018 Accepted: 27 November 2018
References
1. Chun TW, Davey RT Jr, Engel D, Lane HC, Fauci AS. Re-emergence of HIV
after stopping therapy. Nature. 1999;401:874–5.
2. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early
establishment of a pool of latently infected, resting CD4(+) T cells during
primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869–73.
3. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C,
Gange SJ, Siliciano RF. Long-term follow-up studies confirm the stability of
the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003;9:727–8.
4. Crooks AM, Bateson R, Cope AB, Dahl NP, Griggs MK, Kuruc JD, Gay CL,
Eron JJ, Margolis DM, Bosch RJ, Archin NM. Precise quantitation of the
latent HIV-1 reservoir: implications for eradication strategies. J Infect Dis.
2015;212:1361–5.
5. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M,
Chadwick K, Margolick J, Quinn TC, et al. Quantification of latent tissue
reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–8.
6. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B,
Boucher G, Boulassel MR, Ghattas G, Brenchley JM, et al. HIV reservoir size
and persistence are driven by T cell survival and homeostatic proliferation.
Nat Med. 2009;15:893–900.
7. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ,
Hanifin JM, Slifka MK. Duration of antiviral immunity after smallpox
vaccination. Nat Med. 2003;9:1131–7.
8. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, Martin-Gayo E, Leng J,
Henrich TJ, Li JZ, et al. HIV-1 persistence in CD4+ T cells with stem cell-like
properties. Nat Med. 2014;20:139–42.
9. Tanel A, Fonseca SG, Yassine-Diab B, Bordi R, Zeidan J, Shi Y, Benne C,
Sekaly RP. Cellular and molecular mechanisms of memory T-cell survival.
Expert Rev Vaccines. 2009;8:299–312.
10. Nischang M, Sutmuller R, Gers-Huber G, Audige A, Li D, Rochat MA,
Baenziger S, Hofer U, Schlaepfer E, Regenass S, et al. Humanized mice
recapitulate key features of HIV-1 infection: a novel concept using long-
acting anti-retroviral drugs for treating HIV-1. PLoS One. 2012;7:e38853.
11. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD,
Chateau M, Nochi T, Krisko JF, Spagnuolo RA, et al. Generation of HIV
latency in humanized BLT mice. J Virol. 2012;86:630–4.
12. Arainga M, Su H, Poluektova LY, Gorantla S, Gendelman HE. HIV-1 cellular and
tissue replication patterns in infected humanized mice. Sci Rep. 2016;6:23513.
13. Deruaz M, Moldt B, Le KM, Power KA, Vrbanac VD, Tanno S, Ghebremichael
MS, Allen TM, Tager AM, Burton DR, Luster AD. Protection of humanized
mice from repeated Intravaginal HIV challenge by passive immunization: a
model for studying the efficacy of neutralizing antibodies in vivo. J Infect
Dis. 2016;214:612–6.
14. Tsai P, Wu G, Baker CE, Thayer WO, Spagnuolo RA, Sanchez R, Barrett S,
Howell B, Margolis D, Hazuda DJ, et al. In vivo analysis of the effect of
panobinostat on cell-associated HIV RNA and DNA levels and latent HIV
infection. Retrovirology. 2016;13:36.
15. Iordanskiy S, Van Duyne R, Sampey GC, Woodson CM, Fry K, Saifuddin M,
Guo J, Wu Y, Romerio F, Kashanchi F. Therapeutic doses of irradiation
activate viral transcription and induce apoptosis in HIV-1 infected cells.
Virology. 2015;485:1–15.
16. Halper-Stromberg A, Lu CL, Klein F, Horwitz JA, Bournazos S, Nogueira L,
Eisenreich TR, Liu C, Gazumyan A, Schaefer U, et al. Broadly neutralizing
antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs
in humanized mice. Cell. 2014;158:989–99.
17. Kitchen SG, Bennett M, Galic Z, Kim J, Xu Q, Young A, Lieberman A, Joseph
A, Goldstein H, Ng H, et al. Engineering antigen-specific T cells from
genetically modified human hematopoietic stem cells in immunodeficient
mice. PLoS One. 2009;4:e8208.
18. Rongvaux A, Takizawa H, Strowig T, Willinger T, Eynon EE, Flavell RA, Manz
MG. Human Hemato-lymphoid system mice: current use and future
potential for medicine. Annu Rev Immunol. 2013.
19. Bruner KM, Hosmane NN, Siliciano RF. Towards an HIV-1 cure: measuring
the latent reservoir. Trends Microbiol. 2015;23:192–203.
20. Eisele E, Siliciano RF. Redefining the viral reservoirs that prevent HIV-1
eradication. Immunity. 2012;37:377–88.
21. Lin MT, Tseng LH, Kamiyama H, Kamiyama M, Lim P, Hidalgo M, Wheelan S,
Eshleman J. Quantifying the relative amount of mouse and human DNA in
cancer xenografts using species-specific variation in gene length.
Biotechniques. 2010;48:211–8.
22. Wang ND, Li TS. Factors associated with the size of HIV DNA reservoir. Chin
Med J. 2017;130:224–30.
23. Pinzone MR, Graf E, Lynch L, McLaughlin B, Hecht FM, Connors M, Migueles
SA, Hwang WT, Nunnari G, O'Doherty U. Monitoring integration over time
supports a role for cytotoxic T lymphocytes and ongoing replication as
determinants of reservoir size. J Virol. 2016;90:10436–45.
24. Kang W, Zhu W, Li Y, Jiao Y, Zhuang Y, Xie Y, Zhao K, Dang B, Liu Q, Zhang
Y, Sun Y. Analysis of HIV-1c-specific CTL responses with HIV-1 reservoir size
and forms. Viral Immunol. 2016;29:184–91.
25. Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV
persistence: implications for curative approaches to HIV infection. Immunol
Rev. 2013;254:326–42.
26. Depince-Berger AE, Vergnon-Miszczycha D, Girard A, Fresard A, Botelho-
Nevers E, Lambert C, Del Tedesco E, Genin C, Pozzetto B, Lucht F, et al.
Major influence of CD4 count at the initiation of cART on viral and
immunological reservoir constitution in HIV-1 infected patients.
Retrovirology. 2016;13:44.
27. Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselinova M, Pollakis G,
Beloukas A, Vandekerckhove L, Strain M, Richman D, Phillips A, et al. During
stably suppressive antiretroviral therapy integrated HIV-1 DNA load in
peripheral blood is associated with the frequency of CD8 cells expressing
HLA-DR/DP/DQ. EBioMedicine. 2015;2:1153–9.
28. Wagner TA, McLaughlin S, Garg K, Cheung CY, Larsen BB, Styrchak S, Huang
HC, Edlefsen PT, Mullins JI, Frenkel LM. HIV latency. Proliferation of cells with
HIV integrated into cancer genes contributes to persistent infection.
Science. 2014;345:570–3.
29. Maldarelli F, Wu X, Su L, Simonetti FR, Shao W, Hill S, Spindler J, Ferris AL, Mellors
JW, Kearney MF, et al. HIV latency. Specific HIV integration sites are linked to clonal
expansion and persistence of infected cells. Science. 2014;345:179–83.
30. Nischang M, Gers-Huber G, Audige A, Akkina R, Speck RF. Modeling HIV
infection and therapies in humanized mice. Swiss Med Wkly. 2012;142:w13618.
31. Jain V, Hartogensis W, Bacchetti P, Hunt PW, Hatano H, Sinclair E, Epling L,
Lee TH, Busch MP, McCune JM, et al. Antiretroviral therapy initiated within 6
months of HIV infection is associated with lower T-cell activation and
smaller HIV reservoir size. J Infect Dis. 2013;208:1202–11.
32. Spivak AM, Planelles V. HIV-1 eradication: early trials (and tribulations).
Trends Mol Med. 2016;22:10–27.
33. Rouzioux C, Avettand-Fenoel V. Total HIV DNA: a global marker of HIV
persistence. Retrovirology. 2018;15:30.
34. Koelsch KK, Liu L, Haubrich R, May S, Havlir D, Gunthard HF, Ignacio CC,
Campos-Soto P, Little SJ, Shafer R, et al. Dynamics of total, linear
Rochat et al. Virology Journal          (2018) 15:191 Page 7 of 8
nonintegrated, and integrated HIV-1 DNA in vivo and in vitro. J Infect Dis.
2008;197:411–9.
35. Avettand-Fenoel V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A,
Viard JP, Rouzioux C. Total HIV-1 DNA, a marker of viral reservoir dynamics
with clinical implications. Clin Microbiol Rev. 2016;29:859–80.
36. Besson GJ, Lalama CM, Bosch RJ, Gandhi RT, Bedison MA, Aga E, Riddler SA,
McMahon DK, Hong F, Mellors JW. HIV-1 DNA decay dynamics in blood
during more than a decade of suppressive antiretroviral therapy. Clin Infect
Dis. 2014;59:1312–21.
37. Hocqueloux L, Avettand-Fenoel V, Jacquot S, Prazuck T, Legac E, Melard A,
Niang M, Mille C, Le Moal G, Viard JP, et al. Long-term antiretroviral therapy
initiated during primary HIV-1 infection is key to achieving both low HIV
reservoirs and normal T cell counts. J Antimicrob Chemother. 2013;68:1169–78.
38. Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M,
Vandekerckhove L. Integrated and Total HIV-1 DNA predict ex vivo viral
outgrowth. PLoS Pathog. 2016;12:e1005472.
39. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, Dandekar
S. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary
human immunodeficiency virus type 1 infection and substantial delay in
restoration following highly active antiretroviral therapy. J Virol. 2003;77:
11708–17.
40. Milling SW, Jenkins CD, Yrlid U, Cerovic V, Edmond H, McDonald V, Nassar
M, Macpherson G. Steady-state migrating intestinal dendritic cells induce
potent inflammatory responses in naive CD4+ T cells. Mucosal Immunol.
2009;2:156–65.
41. Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG,
Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, et al. Persistent HIV-1
replication is associated with lower antiretroviral drug concentrations in
lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111:2307–12.
42. Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, Hunt P, Martin
JN, Kahn JO, Levy J, et al. Immune activation set point during early HIV
infection predicts subsequent CD4+ T-cell changes independent of viral
load. Blood. 2004;104:942–7.
43. Claiborne DT, Prince JL, Scully E, Macharia G, Micci L, Lawson B, Kopycinski J,
Deymier MJ, Vanderford TH, Nganou-Makamdop K, et al. Replicative fitness
of transmitted HIV-1 drives acute immune activation, proviral load in
memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A.
2015;112:E1480–9.
44. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN,
McCune JM, Hecht F, et al. Cell-based measures of viral persistence are
associated with immune activation and programmed cell death protein 1
(PD-1)-expressing CD4+ T cells. J Infect Dis. 2013;208:50–6.
45. Murray JM, Zaunders JJ, McBride KL, Xu Y, Bailey M, Suzuki K, Cooper DA,
Emery S, Kelleher AD, Koelsch KK, Team PS. HIV DNA subspecies persist in
both activated and resting memory CD4+ T cells during antiretroviral
therapy. J Virol. 2014;88:3516–26.
46. Carr JM, Cheney KM, Coolen C, Davis A, Shaw D, Ferguson W, Chang G,
Higgins G, Burrell C, Li P. Development of methods for coordinate
measurement of total cell-associated and integrated human
immunodeficiency virus type 1 (HIV-1) DNA forms in routine clinical
samples: levels are not associated with clinical parameters, but low levels of
integrated HIV-1 DNA may be prognostic for continued successful therapy.
J Clin Microbiol. 2007;45:1288–97.
47. Barata JT, Silva A, Abecasis M, Carlesso N, Cumano A, Cardoso AA. Molecular
and functional evidence for activity of murine IL-7 on human lymphocytes.
Exp Hematol. 2006;34:1133–42.
48. Sheth PM, Chege D, Shin LY, Huibner S, Yue FY, Loutfy M, Halpenny R,
Persad D, Kovacs C, Chun TW, et al. Immune reconstitution in the sigmoid
colon after long-term HIV therapy. Mucosal Immunol. 2008;1:382–8.
49. Yukl SA, Gianella S, Sinclair E, Epling L, Li Q, Duan L, Choi AL, Girling V, Ho T,
Li P, et al. Differences in HIV burden and immune activation within the gut
of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect
Dis. 2010;202:1553–61.
50. Arainga M, Edagwa B, Mosley RL, Poluektova LY, Gorantla S, Gendelman HE.
A mature macrophage is a principal HIV-1 cellular reservoir in humanized
mice after treatment with long acting antiretroviral therapy. Retrovirology.
2017;14:17.
51. Choudhary SK, Archin NM, Cheema M, Dahl NP, Garcia JV, Margolis DM.
Latent HIV-1 infection of resting CD4 T cells in the humanized Rag2/
gammac/ mouse. J Virol. 2012;86:114–20.
52. Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, Bristol
G, An DS, Zack JA. HIV latency in the humanized BLT mouse. J Virol. 2012;
86:339–47.
53. Lavender KJ, Pace C, Sutter K, Messer RJ, Pouncey DL, Cummins NW,
Natesampillai S, Zheng J, Goldsmith J, Widera M, et al. An advanced BLT-
humanized mouse model for extended HIV-1 cure studies. AIDS. 2018;32:1–10.
54. Marsden MD, Loy BA, Wu X, Ramirez CM, Schrier AJ, Murray D, Shimizu A,
Ryckbosch SM, Near KE, Chun TW, et al. In vivo activation of latent HIV with
a synthetic bryostatin analog effects both latent cell "kick" and "kill" in
strategy for virus eradication. PLoS Pathog. 2017;13:e1006575.
55. Melkus MW, Estes JD, Padgett-Thomas A, Gatlin J, Denton PW, Othieno FA,
Wege AK, Haase AT, Garcia JV. Humanized mice mount specific adaptive and
innate immune responses to EBV and TSST-1. Nat Med. 2006;12:1316–22.
56. Deruaz M, Tager AM. Humanized mouse models of latent HIV infection. Curr
Opin Virol. 2017;25:97–104.
Rochat et al. Virology Journal          (2018) 15:191 Page 8 of 8
